Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases | Zendy

Tsukasa Ito-Horiyama | Zendy; Yoshikazu Ishii | Zendy; Akinobu Ito | Zendy; Takafumi Sato | Zendy; Rio Nakamura | Zendy; Norio Fukuhara | Zendy; Masakatsu Tsuji | Zendy; Yoshinori Yamano | Zendy; Keizo Yamaguchi | Zendy; Kazuhiro Tateda | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

Author(s) -

Tsukasa Ito-Horiyama,

Yoshikazu Ishii,

Akinobu Ito,

Takafumi Sato,

Rio Nakamura,

Norio Fukuhara,

Masakatsu Tsuji,

Yoshinori Yamano,

Keizo Yamaguchi,

Kazuhiro Tateda

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.03098-15

Subject(s) - meropenem , cephalosporin , hydrolysis , carbapenem , siderophore , chemistry , microbiology and biotechnology , nuclear chemistry , antibiotics , biology , biochemistry , antibiotic resistance , gene

To better understand the antibacterial activity of S-649266 against carbapenemase producers, its stability against clinically relevant carbapenemases was investigated. The catalytic efficiencies (k cat /Km ) of IMP-1, VIM-2, and L1 for S-649266 were 0.0048, 0.0050, and 0.024 μM−1 s−1 , respectively, which were more than 260-fold lower than that for meropenem. Only slight hydrolysis of S-649266 against KPC-3 was observed. NDM-1 hydrolyzed meropenem 3-fold faster than S-649266 at 200 μM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research